$SSY
SUNLINK HEALTH SYSTEMS INC

2017 Q4 Form 10-Q Financial Statement

#000119312518045737 Filed on February 14, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2016 Q4
Revenue $13.88M $14.26M
YoY Change -2.64% -14.05%
Cost Of Revenue $662.0K $713.0K
YoY Change -7.15% -18.98%
Gross Profit $13.22M $13.54M
YoY Change -2.41% -13.77%
Gross Profit Margin 95.23% 95.0%
Selling, General & Admin $4.240M $7.220M
YoY Change -41.27% -28.23%
% of Gross Profit 32.08% 53.32%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $280.0K $470.0K
YoY Change -40.43% 4.44%
% of Gross Profit 2.12% 3.47%
Operating Expenses $4.300M $8.800M
YoY Change -51.14% -29.49%
Operating Profit -$80.00K $28.00K
YoY Change -385.71% -102.22%
Interest Expense $119.0K $157.0K
YoY Change -24.2% -24.88%
% of Operating Profit 560.71%
Other Income/Expense, Net $480.0K $1.110M
YoY Change -56.76% -43.65%
Pretax Income $503.0K $2.577M
YoY Change -80.48% -275.9%
Income Tax -$296.0K -$372.0K
% Of Pretax Income -58.85% -14.44%
Net Earnings $726.0K $3.098M
YoY Change -76.57% -133.15%
Net Earnings / Revenue 5.23% 21.73%
Basic Earnings Per Share $0.08 $0.33
Diluted Earnings Per Share $0.08 $0.33
COMMON SHARES
Basic Shares Outstanding 8.688M 9.443M shares
Diluted Shares Outstanding 8.758M 9.450M shares

Balance Sheet

Concept 2017 Q4 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.000M $14.40M
YoY Change -79.17% 289.19%
Cash & Equivalents $2.959M $14.38M
Short-Term Investments
Other Short-Term Assets $4.100M $2.700M
YoY Change 51.85% 8.0%
Inventory $2.149M $2.153M
Prepaid Expenses
Receivables $6.400M $6.600M
Other Receivables $0.00 $0.00
Total Short-Term Assets $15.53M $25.86M
YoY Change -39.96% 36.16%
LONG-TERM ASSETS
Property, Plant & Equipment $10.55M $10.83M
YoY Change -2.61% -50.96%
Goodwill $461.0K
YoY Change 0.0%
Intangibles $1.529M $2.624M
YoY Change -41.73% -5.13%
Long-Term Investments
YoY Change
Other Assets $758.0K $866.0K
YoY Change -12.47% -38.14%
Total Long-Term Assets $13.13M $14.78M
YoY Change -11.17% -44.66%
TOTAL ASSETS
Total Short-Term Assets $15.53M $25.86M
Total Long-Term Assets $13.13M $14.78M
Total Assets $28.66M $40.64M
YoY Change -29.49% -11.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.765M $2.486M
YoY Change -29.0% -47.07%
Accrued Expenses $307.0K $461.0K
YoY Change -33.41% -36.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $263.0K $499.0K
YoY Change -47.29% -93.95%
Total Short-Term Liabilities $5.438M $7.173M
YoY Change -24.19% -60.13%
LONG-TERM LIABILITIES
Long-Term Debt $2.929M $6.464M
YoY Change -54.69% 93.94%
Other Long-Term Liabilities $258.0K $302.0K
YoY Change -14.57% -53.68%
Total Long-Term Liabilities $4.016M $7.806M
YoY Change -48.55% 52.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.438M $7.173M
Total Long-Term Liabilities $4.016M $7.806M
Total Liabilities $9.454M $14.98M
YoY Change -36.88% -35.22%
SHAREHOLDERS EQUITY
Retained Earnings $4.785M $7.769M
YoY Change -38.41% 64.7%
Common Stock $14.75M $18.32M
YoY Change -19.49% 0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.20M $25.70M
YoY Change
Total Liabilities & Shareholders Equity $28.66M $40.64M
YoY Change -29.49% -11.08%

Cashflow Statement

Concept 2017 Q4 2016 Q4
OPERATING ACTIVITIES
Net Income $726.0K $3.098M
YoY Change -76.57% -133.15%
Depreciation, Depletion And Amortization $280.0K $470.0K
YoY Change -40.43% 4.44%
Cash From Operating Activities $40.00K -$720.0K
YoY Change -105.56% 620.0%
INVESTING ACTIVITIES
Capital Expenditures $388.0K $564.0K
YoY Change -31.21% 55.8%
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.940M
YoY Change -100.0%
Cash From Investing Activities -$390.0K $4.370M
YoY Change -108.92% -1281.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.590M -2.070M
YoY Change 218.36% 613.79%
NET CHANGE
Cash From Operating Activities 40.00K -720.0K
Cash From Investing Activities -390.0K 4.370M
Cash From Financing Activities -6.590M -2.070M
Net Change In Cash -6.940M 1.580M
YoY Change -539.24% -307.89%
FREE CASH FLOW
Cash From Operating Activities $40.00K -$720.0K
Capital Expenditures $388.0K $564.0K
Free Cash Flow -$348.0K -$1.284M
YoY Change -72.9% 177.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7416814 shares
CY2016Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
792000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
732000
CY2016Q4 us-gaap Assets
Assets
40643000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14379000
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
500000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
545000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
307000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
15526000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19124000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
11038000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1765000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6905000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-327000
CY2017Q4 us-gaap Assets
Assets
28658000
CY2017Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
2000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2959000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7417000 shares
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7417000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
3708000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7921000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1932000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9163000 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
4581000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2098000
CY2017Q2 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0
CY2017Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
296000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1529000
CY2017Q4 us-gaap Inventory Net
InventoryNet
2149000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28658000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4016000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5438000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
3419000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
263000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2929000
CY2017Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
2583000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1171000
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
12700000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
758000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
258000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2017Q4 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4058000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10549000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29673000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6360000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4785000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19204000
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
227000
CY2017Q4 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
829000
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
991000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3261000
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
552000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
22621000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18319000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
13103000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1571000
CY2017Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6458000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-327000
CY2017Q2 us-gaap Assets
Assets
35336000
CY2017Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
12000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10494000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9163000 shares
CY2017Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2017Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1587000
CY2017Q2 us-gaap Inventory Net
InventoryNet
2159000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35336000
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1329000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12314000
CY2017Q2 us-gaap Long Term Debt
LongTermDebt
7203000
CY2017Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
6710000
CY2017Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2017Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
2425000
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1277000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
838000
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
289000
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2017Q2 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3062000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10290000
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28609000
CY2017Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
5906000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4336000
CY2017Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
21693000
CY2017Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
493000
CY2017Q2 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
1040000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1004000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
71000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11118000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6121000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-189000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
10069000
us-gaap Cost Of Services
CostOfServices
1421000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-39000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
910000
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
7147000
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
4422000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
2725000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-243000
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
137000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
3017000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
1699000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9443000 shares
ssy Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
27438000
ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
808000
ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
0
dei Amendment Flag
AmendmentFlag
false
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.18
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.47
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
33000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1471000
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.18
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.47
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-228000
us-gaap Interest Expense
InterestExpense
378000
us-gaap Interest Paid
InterestPaid
206000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
11604000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18748000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3716000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3914000
us-gaap Net Income Loss
NetIncomeLoss
6121000
us-gaap Operating Income Loss
OperatingIncomeLoss
-925000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
267000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2821000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
808000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
14620000
us-gaap Proceeds From Sale Of Other Assets1
ProceedsFromSaleOfOtherAssets1
4936000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
216000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3716000
us-gaap Sales Revenue Net
SalesRevenueNet
27301000
us-gaap Supplies Expense
SuppliesExpense
918000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9449000 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
451000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7535000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
449000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-296000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
9550000
us-gaap Cost Of Services
CostOfServices
1349000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation And Amortization
DepreciationAndAmortization
868000
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
-126000
us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-126000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
0
dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
dei Entity Registrant Name
EntityRegistrantName
SUNLINK HEALTH SYSTEMS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000096793
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
944000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-238000
us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
230000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-2000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
575000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.06
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
279000
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.06
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-296000
us-gaap Interest Expense
InterestExpense
246000
us-gaap Interest Paid
InterestPaid
218000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2587000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2946000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1072000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Sale Of Other Assets1
ProceedsFromSaleOfOtherAssets1
2000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
208000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
11652000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Note 4. &#x2013; Economic Damages Claim</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010. In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys&#x2019; fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the three and six months ended December&#xA0;31, 2017 and as of December&#xA0;31, 2017, the net settlements of $944 are included in Prepaid expense and other assets on the December&#xA0;31, 2017 Condensed Consolidated Balance Sheets.</p> </div>
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>Note 2. &#x2013; Business Operations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <u>Business Operations</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an&#xA0;<font style="WHITE-SPACE: nowrap">84-bed</font>&#xA0;community hospital and a&#xA0;<font style="WHITE-SPACE: nowrap">66-bed</font>&#xA0;nursing home in Mississippi, a&#xA0;<font style="WHITE-SPACE: nowrap">100-bed</font>&#xA0;nursing home in Georgia, an IT service company, and healthcare facilities which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The business strategy of SunLink is to focus its efforts on expanding the services and improving the operations and profitability of its existing Healthcare Services and Pharmacy businesses. The Company is investing in upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses, while seeking to sell certain of its subsidiaries&#x2019; underperforming assets.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares in tender offers completed in February and December 2017. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to improve its existing businesses, make acquisitions of Healthcare Services and Pharmacy businesses, prepay debts, return capital to shareholders including through potential public or private purchases of shares, and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company&#x2019;s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On January&#xA0;11, 2018, Carmichael&#x2019;s Cashway Pharmacy, Inc., a wholly owned subsidiary of the Company, sold the assets of a retail pharmacy operation it operates for approximately $410. A pre-tax gain on the sale of the assets of approximately $188 will be reported in results for the three months ended March&#xA0;31, 2018.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Throughout these notes to the consolidated financial statements, all references to &#x201C;SunLink,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; &#x201C;ours,&#x201D; &#x201C;us&#x201D; and the &#x201C;Company&#x201D; refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to &#x201C;we,&#x201D; &#x201C;our,&#x201D; &#x201C;ours,&#x201D; and &#x201C;us&#x201D; in such context refer to the operations.</p> </div>
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1070000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6730000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
265000
us-gaap Net Income Loss
NetIncomeLoss
449000
us-gaap Operating Income Loss
OperatingIncomeLoss
-179000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
314000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3784000
us-gaap Sales Revenue Net
SalesRevenueNet
27241000
us-gaap Supplies Expense
SuppliesExpense
913000
dei Trading Symbol
TradingSymbol
SSY
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9196000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9125000 shares
ssy Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
27471000
ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
1072000
ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
21000
ssy Net Operating Loss Carryforward Expiration Year
NetOperatingLossCarryforwardExpirationYear
2025
CY2016Q4 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
ssy Accrued Penalty Expense
AccruedPenaltyExpense
170000
ssy Number Of Hospitals Sold
NumberOfHospitalsSold
3 Hospital
CY2016Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
274000
CY2016Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2016Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3098000
CY2016Q4 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-399000
CY2016Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5433000
CY2016Q4 us-gaap Cost Of Services
CostOfServices
713000
CY2016Q4 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
27000
CY2016Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
466000
CY2016Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
240000
CY2016Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
149000
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2016Q4 us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
91000
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2016Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-289000
CY2016Q4 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
104000
CY2016Q4 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2995000
CY2016Q4 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
2949000
CY2016Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.31
CY2016Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.02
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2577000
CY2016Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.31
CY2016Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.02
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-372000
CY2016Q4 us-gaap Interest Expense
InterestExpense
157000
CY2016Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
5759000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
3098000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
28000
CY2016Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2016Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
138000
CY2016Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1111000
CY2016Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
564000
CY2016Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
125000
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
14255000
CY2016Q4 us-gaap Supplies Expense
SuppliesExpense
482000
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9450000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9443000 shares
CY2016Q4 ssy Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
14359000
CY2016Q4 ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
0
CY2017Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
197000
CY2017Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29000
CY2017Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
726000
CY2017Q4 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-296000
CY2017Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5092000
CY2017Q4 us-gaap Cost Of Services
CostOfServices
662000
CY2017Q4 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
439000
CY2017Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
-73000
CY2017Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-73000
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2017Q4 us-gaap Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
0
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2017Q4 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
944000
CY2017Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-238000
CY2017Q4 us-gaap Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
160000
CY2017Q4 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-4000
CY2017Q4 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
799000
CY2017Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.09
CY2017Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
503000
CY2017Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.09
CY2017Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-296000
CY2017Q4 us-gaap Interest Expense
InterestExpense
119000
CY2017Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
5888000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
726000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-80000
CY2017Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2017Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
160000
CY2017Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1145000
CY2017Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
388000
CY2017Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
88000
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
13878000
CY2017Q4 us-gaap Supplies Expense
SuppliesExpense
488000
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8758000 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8688000 shares
CY2017Q4 ssy Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
14038000
CY2017Q4 ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
4000

Files In Submission

Name View Source Status
0001193125-18-045737-index-headers.html Edgar Link pending
0001193125-18-045737-index.html Edgar Link pending
0001193125-18-045737.txt Edgar Link pending
0001193125-18-045737-xbrl.zip Edgar Link pending
d502472d10q.htm Edgar Link pending
d502472dex101.htm Edgar Link pending
d502472dex311.htm Edgar Link pending
d502472dex312.htm Edgar Link pending
d502472dex321.htm Edgar Link pending
d502472dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ssy-20171231.xml Edgar Link completed
ssy-20171231.xsd Edgar Link pending
ssy-20171231_cal.xml Edgar Link unprocessable
ssy-20171231_def.xml Edgar Link unprocessable
ssy-20171231_lab.xml Edgar Link unprocessable
ssy-20171231_pre.xml Edgar Link unprocessable